Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | TBXAS1 | P24557 | 10/20 | 0.56 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.55 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.55 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.55 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL727185 | 0.85 | CYP1A2 (0.62) | CHRNA7TDP1TBXAS1CYP11B1CYP11B2 | |
| SCHEMBL78082 | 0.84 | CHRNA7 (0.68) | CHRNA7TDP1CYP19A1HRH4HRH3 | |
| SCHEMBL29995759 | 0.83 | CYP11B1 (0.65) | CHRNA7CYP3A4TBXAS1CYP11B1CYP11B2 | |
| SCHEMBL177863 | 0.83 | CYP11B1 (0.65) | CHRNA7CYP3A4TBXAS1CYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL10665044 | 0.81 | TBXAS1 (0.64) | TBXAS1CYP11B1CYP11B2HRH4HRH3 | |
| Ammonia Solution, Strong SCHEMBL5999508 | 0.81 | CYP11B1 (0.62) | CHRNA7TBXAS1CYP11B1CYP11B2HRH4 | |
| SCHEMBL9593116 | 0.81 | MEN1 (0.55) | CHRNA7CYP3A4TBXAS1CYP11B1CYP11B2 | |
| SCHEMBL6649631 | 0.80 | TBXAS1 (0.56) | CYP3A4TBXAS1CYP11B1CYP11B2HRH4 | |
| SCHEMBL8081819 | 0.80 | ALDH1A1 (0.66) | ALDH1A1TDP1TBXAS1CYP11B1CYP11B2 | |
| SCHEMBL3758352 | 0.80 | TBXAS1 (0.56) | TBXAS1CYP11B1CYP11B2HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279215-A1 | NAMPT MODULATORS | CYTOKINETICS, INCORPORATED | 2024-08-22 | — | — | US | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| EP-3305778-B1 | INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LTD (GB) | 2022-01-19 | — | — | EP | disclosed |
| US-8404683-B2 | Inhibitors of the interaction between MDM2 and P53 | JANSSEN PHARMACEUTICAL N.V. (BE) | 2013-03-26 | — | — | US | disclosed |
| US-20120270878-A1 | INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | BAYER HEALTHERCARE LLC (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120270878-A1 | INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | BAYER HEALTHERCARE LLC (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120149706-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | DUMAS JACQUES (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149706-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | DUMAS JACQUES (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120129893-A1 | Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas | DUMAS JACQUES (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120129893-A1 | Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas | DUMAS JACQUES (US) | 2012-05-24 | — | — | US | disclosed |
| US-4975438-A | ANTICOAGULANT | HOFFMANN-LA ROCHE INC. (US) | 1990-12-04 | — | — | US | disclosed |
| US-4917826-A | TREATING DIABETES AND OBESITY | THE UPJOHN COMPANY (US) | 1990-04-17 | — | — | US | disclosed |
| EP-0299379-A1 | Pentadienamide PAF-antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 1989-01-18 | — | — | EP | disclosed |
| US-4788206-A | CARDIOVASCULAR DISORDERS, PLATELETS | HOFFMANN-LA ROCHE INC. (US) | 1988-11-29 | — | — | US | disclosed |
| EP-0104727-B1 | PYRIDINYL-SUBSTITUTED BENZIMIDAZOLES AND QUINOXALINES | THE UPJOHN COMPANY (US) | 1986-12-03 | — | — | EP | disclosed |
| US-4495357-A | THROMBOXANE A2 SYNTHETASE INHIBITORS | THE UPJOHN COMPANY (US) | 1985-01-22 | — | — | US | disclosed |
| US-4490531-A | THROMBOXAN INHIBITOR, ANTITUMOR AGENT, HYPOTENSIVE AGENT | THE UPJOHN COMPANY (US) | 1984-12-25 | — | — | US | disclosed |
| EP-0104727-A1 | Pyridinyl-substituted benzimidazoles and quinoxalines | THE UPJOHN COMPANY (US) | 1984-04-04 | — | — | EP | disclosed |
| US-4430502-A | Pyridinyl substituted benzimidazoles and quinoxalines | THE UPJOHN COMPANY (US) | 1984-02-07 | — | — | US | disclosed |
| EP-0069521-A2 | Pyridinyl and imidazolyl derivatives of benzofurans and benzothiophenes | THE UPJOHN COMPANY (US) | 1983-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149706-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | MAPK1, MAP3K1, MAP3K7 | CHRNA7 4727/4885CYP3A4 1809/4885ALDH1A1 1451/4885 |
| US-20230133132-A1 | NAMPT MODULATORS | NAMPT, MC4R, SIRT1 | CHRNA7 2536/4885CYP3A4 2794/4885ALDH1A1 2019/4885 |
| US-20240279215-A1 | NAMPT MODULATORS | NAMPT, SIRT1, NNT | CHRNA7 2605/4885CYP3A4 2932/4885ALDH1A1 758/4885 |
| US-20120270878-A1 | INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | MAP2K2, MAPK1, MAP2K1 | CHRNA7 4701/4885CYP3A4 2132/4885ALDH1A1 1875/4885 |
| US-20120129893-A1 | Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas | BRAF, RAF1, ARAF | CHRNA7 4848/4885CYP3A4 4030/4885ALDH1A1 2759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.